Treatment Mechanisms Explained

Overall Framework of ADPKD Treatment

ADPKD tratamiento can be divided into three levels:

1. Symptomatic tratamiento: Control complicacións like presión arterial, pain, infection — improves calidad de vida and slows función renal decline.
2. Cause-targeted tratamiento: Tolvaptan directly targets the core crecimiento de quistes pathway (V2R-cAMP), slowing disease progresión.
3. Replacement therapy: Dialysis and trasplante renal for enfermedad renal en estadio terminal.

This page explains the mechanism of each tratamiento, helping you understand "why this drug" and "how it works."

ACEI/ARB: Standard Renoprotective Therapy

Mechanism of Action

ACEI (angiotensin-converting enzima inhibitors, "-pril" drugs) and ARB (angiotensin II receptor blockers, "-sartan" drugs) both act on the renin-angiotensin-aldosterone system (RAAS):

• ACEI: Inhibits angiotensin II production.
• ARB: Blocks angiotensin II from binding AT1 receptores.

The core renoprotective mechanism is dilating efferent arterioles > afferent arterioles, lowering glomerular internal pressure. Normally, angiotensin II constricts efferent arterioles to maintain glomerular filtración pressure; blocking it dilates efferent arterioles, reducing glomerular pressure and mitigating hipertensión and hyperfiltración injury.

Additionally, RAAS blockade reduces:

• Angiotensin II's pro-fibrotic effects (via TGF-β).
• Aldosterone's pro-fibrotic and sodio-retaining effects.
• Oxidative estrés and inflamación.

Special Significance in ADPKD

ADPKD pacientes show early RAAS activation — quiste compression of intrarenal vessels causes ischemia, stimulating juxtaglomerular apparatus renin secreción. This is the core mechanism of early ADPKD hipertensión. Therefore ACEI/ARB for ADPKD pacientes is not just antihypertensive — it directly targets the disease pathology.

Clinical Evidence

The HALT-PKD estudio (largest ADPKD-specific antihypertensive estudio) compared:

• Standard BP control (130/80) vs strict BP control (110/75).
• ACEI monotherapy (lisinopril) vs ACEI + ARB combination (lisinopril + telmisartan).

Results:

• Strict BP control slowed TKV growth in early pacientes, but no significant difference in eGFR decline.
• ACEI + ARB combination was not superior to ACEI monotherapy — combination didn't increase renoprotective beneficio but increased hyperkalemia and acute eGFR decline riesgo.
• Therefore, ACEI and ARB combination is not recommended.

Usage Notes

• Initial eGFR decline: eGFR may drop 10-15% after starting ACEI/ARB — this is the expected response to efferent arteriole dilation, not riñón damage. If decline <30% and stable, can continue.
• Potassium monitoreo: ACEI/ARB reduce aldosterone, may raise potasio. Regular monitoreo needed, especially with reduced función renal.
• Cough: ACEI inhibits bradykinin degradation, ~10-20% of pacientes develop dry cough. Can switch to ARB.
• Pregnancy contraindication: ACEI and ARB are teratogenic — women planning embarazo must switch medicamentos beforehand.
• Don't stop on your own: Sudden ACEI/ARB discontinuation may cause BP rebound and acute glomerular pressure elevation.

Tolvaptan: The Only Cause-Targeted Treatment

Mechanism of Action

Tolvaptan is a vasopresina receptor V2 (V2R) antagonist. As described previously, the V2R-cAMP pathway is the core driver of ADPKD crecimiento de quistes:

1. Vasopressin binds V2R on conducto colector principal célula surface.
2. Activates adenylyl cyclase 6 (AC6) via Gs proteína, genrating cAMP.
3. cAMP promotes quiste epithelial proliferación via B-Raf → MEK → ERK pathway.
4. cAMP drives fluid secreción via PKA → CFTR pathway.

Tolvaptan blocks V2R, reducing cAMP production, thereby simultaneously inhibiting quiste célula proliferación and fluid secreción — currently the only tratamiento directly targeting ADPKD pathology.

Clinical Evidence

• TEMPO 3:4 (early pacientes, eGFR ≥60): 3-year RCT, tolvaptán slowed TKV growth ~50%, slowed eGFR decline ~1 mL/min/year. Extension trial showed sustained long-term beneficio.
• REPRISE (mid-late pacientes, eGFR 25-60): Tolvaptan slowed eGFR decline ~1 mL/min/year, but less efectivo than in early disease.
• TEMPO 4:4 extension: Renoprotective effect partially reversed after stopping, suggesting need for continuous tratamiento.

Suitable Population (KDIGO 2025)

Tolvaptan is suitable for ADPKD pacientes at high riesgo of rapid progresión:

• PROPKD score high riesgo (based on genotype, TKV growth rate, eGFR trend).
• Typical age 18-55, eGFR >25 mL/min/1.73m².
• TKV growth rate >5%/year or Mayo class 1C-1E.

Not suitable for:

• Slow progressors (PKD2 mutacións, slow TKV growth).
• eGFR <25 (limited beneficio, increased efecto secundario riesgo).
• Those who cannot tolerate polyuria/polydipsia efecto secundarios.
• Those with hígado disease history or abnormal hígado function (hepatotoxicity riesgo).

Side Effects and Management

• Polyuria/polydipsia (aquaretic effect): Tolvaptan blocks V2R, increasing free water excreción — daily orina volume may reach 3-6 liters. This is the drug working, not a efecto secundario, but severely affects calidad de vida. Need toilet access at all times.
• Thirst and dehydration: Need continuous ingesta de agua to prevent dehydration and hypernatremia.
• Hepatotoxicity: ~4-5% of TEMPO trial pacientes had hígado enzima elevation (>3x upper limit of normal), usually recovering after stopping. Regular hígado function monitoreo needed (at 2 weeks, 4 weeks, 18 months after starting, then every 3 months).
• Hypernatremia: Free water excreción may raise serum sodio — monitor electrolytes.

Important Reminders

• Tolvaptan cannot cure ADPKD — only slows progresión.
• Effect varies by individual — no guarantee for all pacientes.
• Requires continuous use — crecimiento de quistes resumes after stopping.
• The decision requires shared decision-making with your doctor, weighing beneficios and efecto secundarios.
• Do not start or stop tolvaptán on your own — requires physician assessment and monitoreo.

Calcium Channel Blockers (CCB): Choice Matters

Mechanism Differences

CCBs dilate vessels by blocking L-type calcio channels in vascular smooth muscle. But different CCBs have different effects on glomerular circulation:

• Dihydropyridine (DHP): Nifedipine, amlodipine — preferentially dilate afferent arterioles, weak effect on efferent. May increase glomerular internal pressure, theoretically unfavorable for riñóns.
• Non-dihydropyridine: Diltiazem, verapamil — dilate both afferent and efferent arterioles, less impact on glomerular pressure.
• T-type CCB: Manidipine, efonidipine — also block T-type calcio channels, dilating both afferent and efferent arterioles, not increasing glomerular pressure, better renoprotective properties.

Use in ADPKD

Based on these mechanism differences:

• ACEI/ARB is first-line for ADPKD hipertensión.
• If ACEI/ARB cannot control BP and a second drug is needed, avoid traditional DHP CCBs (nifedipine, amlodipine) as they may increase glomerular pressure.
• Consider T-type CCB (manidipine) or other antihypertensive classes (β-blockers, α-blockers).
• Manidipine in human estudios showed superior proteínauria reduction vs amlodipine when combined with ACEI.

Practical Advice

• If you're currently on amlodipine with good BP control, don't stop on your own — discuss with your doctor whether adjustment is needed.
• When choosing antihypertensive combinations, discuss each drug's riñón impact with your doctor.
• CCB choice is only part of BP strategy — reaching BP target is more important.

Surgical and Interventional Treatments

Cyst Aspiration and Sclerotherapy

For single large quistes causing significant pain, ecografía or CT-guided aspiration can be performed, followed by injecting a sclerosing agent (e.g., absolute ethanol) to destroy the quiste lining and cause it to collapse.

• Indication: Single or few large quistes causing localized pain.
• Limitations: Not for diffuse polyquisteic riñóns; cannot improve función renal; riesgo of bleeding, infection, and recurrence.
• Effectiveness: ~60-90% pain relief, but some pacientes recur.

Laparoscopic Cyst Decortication

Laparoscopic surgery to remove quiste roofs, causing quistes to collapse. Suitable for multiple large quistes causing pain or compression.

• Indication: Multiple large quistes causing pain, early satiety (compressing stomach), breathing difficulty (compressing diaphragm).
• Limitations: Cannot improve función renal; surgical riesgos of infection, bleeding, adhesions; may accelerate función renal decline (surgical trauma).
• Guideline position: KDIGO 2025 suggests considering at experienced centers in carefully selected pacientes, not as routine tratamiento.

Nephrectomy

Before trasplante renal, pacientes with extremely enlarged riñóns, recurrent infections, bleeding, or difficult-to-control hipertensión may need native riñón removal. This is major surgery requiring individualized assessment.

Native Kidney Management Before Transplant

Not all ADPKD pacientes need native nephrectomy before trasplante. Whether to retain or remove native riñóns depends on the following factors, requiring joint assessment by trasplante surgery and nefrología:

• Reasons to retain native riñóns: Native riñóns may still produce some orina, helping with fluid management; native nephrectomy is major surgery with bleeding and infection riesgos.
• Indications for removal: Recurrent infección de quistes or bleeding, difficult-to-control severe hipertensión, massively enlarged riñóns compressing the abdomen and affecting trasplante riñón placement, suspected or confirmed riñón tumor.
• Surgical timing: May be estadiod before trasplante, or managed concurrently during trasplante — the specific approach is decided by the trasplante team based on paciente condition.
• Surgical approach: Laparoscopic vs open surgery depends on riñón size, degree of adhesion, and surgical team experience.

Surgical Management of Cyst Infection

Kidney infección de quiste is not rare in ADPKD. Most cases are first treated with antibiotics that penetrate the quiste wall (such as fluoroquinolones), but surgical intervention may be needed in the following situations:

• Inadequate antibiotic response: Fever and pain not improving after 1-2 weeks of standard antibiotic therapy — evaluate whether drainage is needed.
• Cyst abscess formation: When imaging confirms pus accumulation, percutaneous catheter drainage under ecografía or CT guidance may be required.
• Complex or multifocal infection: Multiple infection sites or concurrent stones/obstruction may require joint evaluation by urología and infectious disease.
• Recurrent infection of the same quiste: Repeated infections may indicate loss of structural integrity of that quiste — surgical evaluation for removal may be needed.

Management Pathway for Cyst Hemorrhage

Kidney quiste hemorrhage is common in ADPKD, presenting as sudden dolor en el flanco with gross hematuria. Most sangrado de quiste resolves spontaneously. The management pathway is typically:

• Conservative management (most cases): Rest, hydration, analgesia (avoid NSAIDs to prevent worsening bleeding) — most bleeding stops within days to 2 weeks.
• When to seek care: Heavy hematuria causing clot obstruction of the urinario tract, persistent bleeding beyond 2 weeks, bleeding with fiebre (suggesting possible concurrent infection), bleeding causing significant hemoglobina drop.
• Interventional management: Persistent or massive bleeding may require selective renal artery embolization to preserve función renal.
• Surgical management: Rarely, uncontrolled hemorrhage may require surgery, but this is a last resort.

Assessment of Massive Kidney Mechanical Compression

In some ADPKD pacientes, riñóns enlarge to occupy most of the abdominal cavity, causing a series of mechanical problems. Whether surgical management is needed depends on síntoma severity and quality-of-life impact:

• Possible síntomas: Early satiety, abdominal bloating, dyspnea (diaphragmatic compression), lower-extremity venous return impairment, activity limitation, inadequate nutriciónal intake.
• Assessment: Joint evaluation by nefrología and urología, combining imaging, síntomas, nutriciónal status, and función renal.
• Management options: Cyst decompression or decortication may relieve some compression síntomas, but surgical riesgos and impact on función renal must be weighed. Rarely, nephrectomy may be needed.
• Relationship with diálisis peritoneal: For pacientes planning diálisis peritoneal, massively enlarged riñóns or hígado may affect diálisis space and eficacia — evaluate in advance.

Polyquisteic Liver Disease Treatment

PLD tratamientos include:

• Liver quiste aspiration/sclerotherapy (similar to quiste renals).
• Laparoscopic quiste hepático fenestration.
• Partial hepatectomy (for localized disease).
• Liver trasplante (rare severe cases).
• Somatoestatina analogs (octreotida, lanreotida) can slow hígado crecimiento de quistes but rebound after stopping.

Surgical Management of Liver Cyst Infection

Liver infección de quiste is uncommon in ADPKD pacientes with PLD, but can be serious when it occurs, typically requiring collaboration among hepatobiliary surgery, infectious disease, and imaging/interventional teams:

• Recognition: Fever, right upper quadrant pain, chills, with elevated white blood células or inflammatory markers — imaging to confirm infection location.
• Antibiotic therapy: Start broad-spectrum antibiotics that penetrate the quiste hepático wall, while obtaining blood cultures and quiste fluid cultures (if drained).
• Percutaneous drainage: When imaging confirms pus accumulation, percutaneous catheter drainage under ecografía or CT guidance.
• Surgical intervention: Inadequate drainage response, complex infección de quiste, or concurrent biliary compression may require hepatobiliary surgery.
• Multidisciplinary collaboration: Complex cases should be jointly managed by nefrología, hepatobiliary surgery, infectious disease, and interventional radiology.

TCM Treatment: Understanding "Activating Blood and Resolving Stasis" Mechanism Hypotheses

Traditional Meaning of "Activating Blood and Resolving Stasis"

"Activating blood and resolving stasis" (活血化瘀) is a core TCM tratamiento method. Traditional theory holds that "blood stasis" is a pathological product of many chronic diseases, and this method aims to promote qi and blood circulation and dissipate stasis. In TCM theory of ADPKD, quistes are viewed as "accumulations," treated with blood-activating, stasis-resolving, and softening methods.

Possible Mechanisms from Modern Medicine Perspective

From a modern medicine perspective, "blood-activating and stasis-resolving" drugs may involve the following mechanisms (these are hypotheses with limited evidencia):

• Improving microcirculation: Some blood-activating herbs (e.g., Danshen/Salvia, Chuanxiong/Ligusticum) show microvascular dilation and hemorheology improvement in experimental estudios. ADPKD quiste compression causes peritubular capillary ischemia; improving microcirculation is theoretically beneficial.
• Anti-inflammatory effects: Danshen, Sanqi/Panax notoginseng show NF-κB and inflammatory factor inhibition in célula and animal estudios. ADPKD interstitial inflamación promotes fibrosis.
• Anti-fibrotic effects: Some blood-activating herbs show TGF-β and collagen deposition inhibition in modelo animals. But human evidencia is insufficient.
• Anti-proliferative effects: Some TCM components inhibit quiste epithelial proliferación in vitro, but far less potent than targeted drugs like tolvaptán.

Evidence Status and Limitations

Must be clear:

• Currently no high-quality RCT proves any Chinese herbal formula can slow ADPKD crecimiento de quistes or función renal decline.
• Existing TCM clínico estudios are mostly small-sample, low-quality, lacking controls.
• "Blood activation and stasis resolution" cannot replace basado en evidencia tratamientos like ACEI/ARB and tolvaptán.
• Some herbs are nefrotóxico (e.g., ácido aristolóquico-containing herbs) — seguridad must be confirmed before use.
• TCM-Western drug interactions need attention — blood-activating herbs may increase bleeding riesgo (especially with anticoagulants).

Rational View of TCM

• TCM can serve as adjunctive therapy for síntoma improvement (pain, sleep, ansiedad), but not as primary tratamiento.
• When choosing TCM, always inform your nefrólogo of all herbs you use.
• Avoid ácido aristolóquico-containing herbs (Guan Mu Tong, Guang Fang Ji, Qing Mu Xiang) — they cause irreversible riñón damage.
• Don't believe claims that "TCM can eliminate quistes" or "TCM can cure ADPKD" — these lack scientific evidencia.
• TCM's "blood activation and stasis resolution" theory provides investigación directions, but requires rigorous ensayo clínico validation.

Emerging Treatment Directions

Treatments currently under investigación include:

• SGLT2 inhibitors (dapagliflozin, empagliflozin): Lower glomerular pressure via tubuloglomerular feedback. STOP-PKD and EMPA-PKD trials ongoing.
• GLP-1 receptor agonists (semaglutide): Slow crecimiento de quistes by regulating metabolism in modelo animals. Human trials about to begin.
• Autophagy activators: Rapamycin, carbamazepine, minoxidil efectivo in modelo animals, but human evidencia insufficient.
• Anti-miRNA therapy: E.g., anti-miR-17, significantly inhibits crecimiento de quistes in modelo animals, entering ensayo clínicos.
• Tyrosine kinase inhibitors: E.g., TEAD inhibitors, targeting the Hippo pathway.

These tratamientos cannot be used clínicoly yet — awaiting ensayo clínico results. Do not attempt any experimental tratamiento without medical guidance.

How to Make Shared Decisions with Your Doctor

Understanding tratamiento mechanisms, you can more meaningfully discuss with your doctor:

• How fast is my disease progressing? Do I need cause-targeted therapy (tolvaptán)?
• Is my current antihypertensive regimen optimal? Do I need to adjust CCB type?
• Does my quiste pain need interventional tratamiento?
• Am I suitable for ensayo clínico participation?
• Is TCM adjunctive therapy safe for me?

Remember: All tratamiento decisions should be made under medical guidance. This page helps you understand "why," but cannot replace your doctor's assessment of your individual situation.

← Back to Mechanism